缓激肽受体 (Bradykinin Receptor) 是细胞表面的 G 蛋白偶联受体 (GPCR) 家族成员。缓激肽受体有两种亚型,B1 和 B2。缓激肽受体介导的信号转导在维持心血管稳态、调节疼痛和炎症方面发挥着重要作用。两种受体都通过激活 G 蛋白传递细胞外信号。
缓激肽 B1 受体在健康组织中的表达水平非常低,但在休克或炎症等应激条件下会被诱导,而缓激肽 B2 受体则无处不在且呈组成性表达。缓激肽 B2 受体参与血管舒张、渗透调节、平滑肌收缩和伤害感受器激活。缓激肽 B1 受体和缓激肽 B2 受体已成为治疗靶点,因为它们与炎症性疾病、血管病变、神经病变、肥胖症、糖尿病和癌症有关。B1R 和 B2R 在疾病中可发挥两种不同的作用。激动剂和拮抗剂已被评估为治疗剂。
Bradykinin receptors are cell surface, G protein-coupled receptor (GPCR) family members. There are two subtypes of bradykinin receptors, B1 and B2. Bradykinin receptor-mediated signal transductions play a significant role in maintaining cardiovascular homeostasis, regulating pain and inflammation. Both receptors transduce extracellular signals through the activation of G-proteins.
Bradykinin B1 receptor is expressed at a very low level in healthy tissues, but is induced under stressful conditions such as shock or inflammation, whereas the bradykinin B2 receptor is ubiquitous and is constitutively expressed. Bradykinin B2 receptor is involved in vasodilation, osmoregulation, smooth muscle contraction, and nociceptor activation. Bradykinin B1 receptor and Bradykinin B2 receptor have emerged as therapeutic targets as they are implicated in inflammatory disease, vasculopathy, neuropathy, obesity, diabetes, and cancer. B1R and B2R can hold dichotomous roles in diseases. Agonists and antagonists have been evaluated as therapeutics.
Des-Arg9-[Leu8]-Bradykinin acetate 是一种有效的缓激肽受体1 (B1R) 拮抗剂,可用于肾纤维化研究。
Mergetpa 是一种具有高亲和力的可逆 Arg-carboxypeptidase 抑制剂,可降低 B1R,阻断葡萄糖喂饲大鼠中 IL-1β 蛋白及 mRNA 的过表达,同时显著增加肾皮质中 IL-1β 蛋白的表达,并用于阻断激肽和 B2 受体拮抗剂转化为缺乏 c 端精氨酸的代谢物,还可抑制离体兔主动脉对缓激肽的反应随时间增强、保留全长 SDF-1α 对细胞的趋化活性,以及逆转葡萄糖喂养大鼠的高血糖、过度体重增加、氧化应激标志物水平升高及炎症标志物过表达。
Emorfazone(Pentoil)是一种具有口服活性的非甾体抗炎药,对缓激肽样物质和激肽原的释放具有明显的抑制作用,并具有抗炎和镇痛活性。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号